Radiopharm Theranostics Limited (RADX)
NASDAQ: RADX · Real-Time Price · USD
4.865
-0.085 (-1.72%)
Mar 3, 2026, 4:00 PM EST - Market closed
Radiopharm Theranostics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Radiopharm Theranostics stock have an average target of 15.33, with a low estimate of 12 and a high estimate of 18. The average target predicts an increase of 215.11% from the current stock price of 4.87.
Analyst Consensus: Strong Buy
* Price targets were last updated on Dec 16, 2025.
Analyst Ratings
The average analyst rating for Radiopharm Theranostics stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B. Riley Securities | B. Riley Securities | Strong Buy Reiterates $13 → $16 | Strong Buy | Reiterates | $13 → $16 | +228.88% | Dec 16, 2025 |
| B. Riley Securities | B. Riley Securities | Strong Buy Maintains $15 → $13 | Strong Buy | Maintains | $15 → $13 | +167.21% | Nov 26, 2025 |
| Brookline Capital | Brookline Capital | Strong Buy Initiates $18 | Strong Buy | Initiates | $18 | +269.99% | Jul 21, 2025 |
| Maxim Group | Maxim Group | Strong Buy Initiates $12 | Strong Buy | Initiates | $12 | +146.66% | May 1, 2025 |
| B. Riley Securities | B. Riley Securities | Strong Buy Initiates $15 | Strong Buy | Initiates | $15 | +208.32% | Mar 12, 2025 |
Financial Forecast
Revenue This Year
n/a
from 12.51M
Revenue Next Year
9.32M
EPS This Year
-0.02
from -0.02
EPS Next Year
-0.02
from -0.02
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | n/a | 19.4M | |||
| Avg | n/a | 9.3M | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -0.01 | -0.01 | |
| Avg | -0.02 | -0.02 | |
| Low | -0.03 | -0.03 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.